MIST
Milestone Pharmaceuticals Inc. [MIST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MIST Stock Summary
Top 10 Correlated ETFs
MIST
Top 10 Correlated Stocks
MIST
In the News
MIST Financial details
Company Rating
-
Market Cap
91.95M
Income
-59.13M
Revenue
1000K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
47
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.73
Forward P/E
-
PEG
-3.07
P/S
12.87
P/B
2.61
P/C
-
P/FCF
-1.17
Quick Ratio
9.59
Current Ratio
10.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.47
EPS next Y
-
EPS next Q
-
EPS this Y
2.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
17.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-58%
ROC
-0.77%
Gross Margin
100%
Oper. Margin
-1357%
Profit Margin
-606%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.33-4.49
52W High
-57.57%
52W Low
+69.72%
RSI
56
Rel Volume
4.31
Avg Volume
340.29K
Volume
1.47M
Perf Week
-0.16%
Perf Month
14.68%
Perf Quarter
-14.28%
Perf Half Y
-16.8%
-
-
-
-
Beta
1.77
-
-
Volatility
0.02%, 0.09%
Prev Close
-0.16%
Price
1.6972
Change
-0.16%
Company Profile
- Volume Average 340.29K
- Market Capitalization 91.95M
- Employee 47
- CEO Mr. Joseph G. Oliveto M.B.A.
- Headquarters Montreal,QC,CA
- IPO Date 2019-05-09
-
Website
https://www.milestonepharma.com 
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
